MedTrace Logo

An Investigational Scan (124I-hJAA-F11 PET/CT) for Diagnosing Lung Cancer

NCT06427369 · Status: WITHDRAWN · Phase: PHASE1 · Type: INTERVENTIONAL

Last updated 2024-09-27

No results posted yet for this study

Summary

This phase I trial studies the side effects of 124I-hJAA-F11, and evaluates how well it works in diagnosing lung cancer. 124I-hJAA-F11 uses a known radioactive substance used in imaging called iodine 124 (124I). hJAA-F11 is an experimental (investigational) antibody that is currently being evaluated as a potential treatment for lung cancer. In animal studies, hJAA-F11 has shown anti-tumor activity against tumors bearing the Thomsen-Friedenreich antigen that is found in over 90% of lung cancers. 124I-hJAA-F11 has the 124I radioactive dye attached to this investigational antibody, which may be a potential tool for imaging-based diagnosis of lung cancer.

Conditions

  • Extensive-stage Small-cell Lung Cancer
  • Limited-stage Small-cell Lung Cancer
  • Lung Non-Small Cell Carcinoma
  • Stage IIIA Lung Cancer
  • Stage IV Lung Cancer

Interventions

OTHER

Radioconjugate

1241-hJAA-F11 IV administration

PROCEDURE

Positron Emission Tomography

PET/CT Imaging

PROCEDURE

Computed Tomography

PET/CT Imaging

PROCEDURE

FDG-Positron Emission Tomography and Computed Tomography Scan

FDG PET/CT Imaging

PROCEDURE

Biospecimen Collection

Blood sample collection imaging

Sponsors & Collaborators

  • Roswell Park Cancer Institute

    lead OTHER

Principal Investigators

  • Grace Dy, MD · Roswell Park Comprehensive Cancer Center

Study Design

Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-10-01
Primary Completion
2027-09-01
Completion
2027-09-01
FDA Drug
Yes

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06427369 on ClinicalTrials.gov